HC Wainwright Has Pessimistic Outlook of PRAX Q1 Earnings

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Equities researchers at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Praxis Precision Medicines in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($3.18) for the quarter, down from their prior estimate of ($2.96). HC Wainwright currently has a “Buy” rating and a $105.00 price objective on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines’ Q2 2025 earnings at ($3.64) EPS, Q3 2025 earnings at ($4.15) EPS, Q4 2025 earnings at ($4.16) EPS, FY2025 earnings at ($15.13) EPS, Q1 2026 earnings at ($4.39) EPS, Q2 2026 earnings at ($4.82) EPS, Q3 2026 earnings at ($4.89) EPS, Q4 2026 earnings at ($4.90) EPS, FY2026 earnings at ($18.99) EPS, FY2027 earnings at ($15.64) EPS, FY2028 earnings at ($15.64) EPS and FY2029 earnings at $23.38 EPS.

Praxis Precision Medicines (NASDAQ:PRAX) last released its quarterly earnings data on Friday, February 28th. The company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($2.76) by ($0.18). The business had revenue of $7.48 million during the quarter, compared to analyst estimates of $0.36 million. Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC dropped their price objective on shares of Praxis Precision Medicines from $150.00 to $85.00 and set a “buy” rating for the company in a research note on Monday. Deutsche Bank Aktiengesellschaft initiated coverage on Praxis Precision Medicines in a research note on Tuesday, February 11th. They issued a “buy” rating and a $111.00 price target for the company. Wedbush lowered Praxis Precision Medicines from a “hold” rating to a “strong sell” rating in a research report on Friday, February 28th. Truist Financial dropped their target price on Praxis Precision Medicines from $175.00 to $85.00 and set a “buy” rating for the company in a research report on Monday. Finally, Robert W. Baird cut their price target on Praxis Precision Medicines from $117.00 to $73.00 and set an “outperform” rating on the stock in a research note on Monday. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Praxis Precision Medicines presently has a consensus rating of “Moderate Buy” and an average price target of $123.80.

Praxis Precision Medicines Trading Up 4.5 %

PRAX opened at $37.85 on Wednesday. The company has a market cap of $763.17 million, a P/E ratio of -3.67 and a beta of 2.76. The company’s 50 day moving average is $73.74 and its 200-day moving average is $69.30. Praxis Precision Medicines has a 1-year low of $30.01 and a 1-year high of $91.83.

Institutional Trading of Praxis Precision Medicines

Institutional investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. lifted its position in shares of Praxis Precision Medicines by 5,437.7% in the 4th quarter. Assenagon Asset Management S.A. now owns 559,082 shares of the company’s stock worth $43,027,000 after purchasing an additional 548,986 shares during the period. Janus Henderson Group PLC boosted its position in shares of Praxis Precision Medicines by 77.5% during the 4th quarter. Janus Henderson Group PLC now owns 929,523 shares of the company’s stock valued at $71,621,000 after purchasing an additional 405,957 shares in the last quarter. VR Adviser LLC grew its stake in Praxis Precision Medicines by 40.2% during the fourth quarter. VR Adviser LLC now owns 989,985 shares of the company’s stock worth $76,189,000 after purchasing an additional 283,854 shares during the period. Alyeska Investment Group L.P. bought a new stake in Praxis Precision Medicines in the fourth quarter worth approximately $17,454,000. Finally, Franklin Resources Inc. lifted its stake in Praxis Precision Medicines by 85.6% in the third quarter. Franklin Resources Inc. now owns 445,233 shares of the company’s stock valued at $25,619,000 after buying an additional 205,335 shares during the period. 67.84% of the stock is currently owned by institutional investors.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.